Biochemical assessment of tissue prognostic factors in breast cancer

Breast

Volumn 6, Issue 1, 1997, Pages 31-37

  Blankenstein, M A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; THYMIDINE KINASE; TUMOR MARKER; UROKINASE;

ARTICLE; BIOASSAY; BREAST CANCER; HUMAN; LABORATORY; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; STANDARDIZATION; TUMOR VOLUME;

EID: 0031046854     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(97)90540-3     Document Type: Article

References (36)

1. Balslev I, Axelsson C K, Zedeler K, Rasmussen B B, Carstensen B, Mouridsen H T. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 1994; 32: 281-290.
2. Mansour E G, Ravdin P M, Dressier L. Prognostic factors in early breast carcinoma. Cancer 1994; 74 (Suppl): 381-400.
3. Gasparini G, Pozza F, Harris A L. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 1206-1219.
4. Clark G M. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 1994; 30: 117-126.
5. Sunderland M C, McGuire W L. Hormones and breast cancer. Trends Endocrinol Metab 1991; 2: 72-76.
6. Alexieva-Figusch J, Van Putten W L J, Blankenstein M A, Blonk-van der Wijst J, Klijn J G M. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors and site of relapse in primary breast cancer. Cancer 1988; 15: 758-768
7. Beex L V A M, Peterse J L, Nortier J W R, van Veelen H, Blankenstein M A. Receptoren voor steroidhormonen en mammacarcinoom. Ned Tijdschr Geneeskd 1992;.136: 2056-2060.
8. EORTC Breast Cancer Cooperative Group. Revision of standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 1980; 16: 1513-1516.
9. Koenders A, Thorpe S M (on behalf of the EORTC Receptor Group). Standardization of steroid receptor assays in human breast cancer-IV. Long-term within and between laboratory variation of estrogen and progesterone receptor assays. Eur J Cancer Clin Oncol 1986; 22: 945-952.
10. Blankenstein M A, Benraad T J. Multilaboratory assessment of tissue prognostic factors in breast cancer: the EORTC Receptor Study Group experience. Can J Oncol 1993; 3 (Suppl 2): 58-64.
11. Charpin C, Martin P M, De Victor B et al. Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas: analysis of oestrogen receptor distribution heterogeneity in tissues and correlations with dextran coated charcoal assay and morphological data. Cancer Res 1988; 48: 1578-1586.
12. Aldred D C. Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer? Am J Clin Pathol 1993; 99: 1-3.
13. Tesch M, Shwamma A, Henderson R. Immunohistochemical determination of estrogen and progesterone receptor status in breast cancer. Am J Clin Pathol 1993; 99: 8-12.
14. Molino A, Micciolo R, Turazza M et al. Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 1995; 34: 221-228.
15. Pari F F, Posey, Y F. Discrepancies of biochemical and immunohistochemical estrogen receptor assays in breast cancer. Human Pathol 1988; 19: 960-966.
16. Orr R K. Fraher K M. Parity is associated with axillary nodal involvement in operable breast cancer. Breast Cancer Res Treat 34: 71-76.
17. Seidman J D, Schnaper L A, Aisner S C. Relationship of the invasive component of the primary breast carcinoma to axillary lymph node metastasis. Cancer 1995; 75: 65-71.
18. Pujol P, Hilsenbeck S G, Chamness G C, Elledge R M. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 1994; 74: 1601-1606.
19. Potter J D, Cerhan J R, Sellers T A et al. Progesterone and estrogen receptor and mammary neoplasia in the Iowa's health study: how many kinds of breast cancer are there? Cancer Epidem Biomarkers Prev 1995; 4: 319-326.
20. Ciocca D R, Clark G M, Tandon A K, Fuqua S A W, Welch W J, McGuire W L. Heat shock protein hsp70 with axillary lymph node-negative breast cancer patients: prognostic implications. J Natl Cancer Inst 1993; 85: 570-574.
21. Klijn J G M, Berns P M J J, Schmitz P I M, Foekens J A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13: 3-17.
22. Klijn J G M, Berns P M J J, Schmitz P I M, Foekens J A. Epidermal growth factor receptor (EGF-R) in clinical breast cancer: Update 1993. Endocr Rev Monographs 1993; 1: 171-174.
23. Ravdin P M. Evaluation of Cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 1993; 24: 219-226.
24. Benraad T J, Foekens J A. Hydroxyapatite assay to measure epidermal growth factor receptor in primary human breast tumours. Ann Clin Biochem 1990; 27: 272-273.
25. Tietz N W. Accuracy in clinical chemistry - does anybody care? Clin Chem 1994; 40: 859-861.
26. Blankenstein M A. Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols - experience of the EORTC Receptor Group. Breast Cancer Res Treat 1990; 17: 91-98.
27. Jänicke F, Schmitt M, Pache L et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 1993; 24: 195-208.
28. Foekens J A, Schmitt M, Van Putten W L J et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648-1658.
29. Foekens J A, Look M P, Peters H A, Van Putten W L J, Portengen H, Klijn J G M. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87: 751-756.
30. Foekens J A, Buessecker F, Peters H A et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423-1427.
31. Blankenstein M A, Koehorst S G A, Van ver Kallen C J H et al. Oestrogen receptor independent expression of progestin receptors in human meningioma - a review. J Steroid Biochem Molec Biol 1995; 53: 361-365.
32. Daffada A A I, Johnston S R D, Smith I E, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status. Cancer Res 1995; 55: 288-293.
33. Romain S, Chinot O, Klijn J G M et al. Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients. Br J Cancer 1994; 70: 304-308.
34. Yu H, Giai M, Diamandis E P et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995; 55: 2104-2110.
35. Fuqua S A, Fitzgerald S D, Chamness G C et al. Variant human breast cancer estrogen receptor with constitutive transcriptional activity. Cancer Res 1991; 51: 105-109.
36. Hennipman A, Van Oirschot B A. Smits J, Rijksen G, Staal G E J. Tyrosine kinase activity in breast cancer, benign breast disease and normal breast tissue. Cancer Res 1989; 49: 516-521.